Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 12, 2026, 10:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 59 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Apolipoprotein Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Effects of Mipomersen on Lipid and Lipoprotein Metabolism in Healthy Subjects

NCT01414881
View directory record Official record
Conditions
Healthy Volunteer
Interventions
mipomersen, Placebo
Drug
Lead sponsor
Kastle Therapeutics, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 2, 2016 · Synced Sep 12, 2026, 10:02 PM EDT
Completed Phase 2 Interventional

Tricaprilin in Mild to Moderate Alzheimer's Disease

NCT00142805
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Tricaprilin, Placebo
Drug · Other
Lead sponsor
Cerecin
Industry
Eligibility
50 Years to 90 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
25
States / cities
Phoenix, Arizona • Cerritos, California • Los Alamitos, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2020 · Synced Sep 12, 2026, 10:02 PM EDT
Completed Phase 3 Interventional

Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Carrier)

NCT00575055
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Bapineuzumab 0.5 mg/kg, Placebo Control, Bapineuzumab 1.0 m/kg
Drug
Lead sponsor
JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Industry
Eligibility
50 Years to 88 Years
Enrollment
1,121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
186
States / cities
Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 143 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2013 · Synced Sep 12, 2026, 10:02 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy of APL180 in Healthy Volunteers and Patients With Coronary Heart Disease (CHD)

NCT00568594
View directory record Official record
Conditions
Coronary Heart Disease
Interventions
APL180, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 75 Years
Enrollment
176 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 23, 2020 · Synced Sep 12, 2026, 10:02 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Gene-Environment Interactions in Alzheimer's Disease

NCT00018473
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Not listed
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
Not listed
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2004
U.S. locations
1
States / cities
Bedford, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 20, 2009 · Synced Sep 12, 2026, 10:02 PM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Safety and Efficacy of ISIS 301012 (Mipomersen) in Homozygous Familial Hypercholesterolemia

NCT00607373
View directory record Official record
Conditions
Lipid Metabolism, Inborn Errors, Hypercholesterolemia, Autosomal Dominant, Hyperlipidemias, Metabolic Diseases, Hyperlipoproteinemia Type II, Metabolism, Inborn Errors, Genetic Diseases, Inborn, Infant, Newborn, Diseases, Metabolic Disorder, Congenital Abnormalities, Hypercholesterolemia, Hyperlipoproteinemias, Dyslipidemias, Lipid Metabolism Disorders
Interventions
mipomersen, Placebo
Drug
Lead sponsor
Kastle Therapeutics, LLC
Industry
Eligibility
12 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
Charlotte, North Carolina • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 8, 2016 · Synced Sep 12, 2026, 10:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Mixed Meal Challenge Study

NCT05087823
View directory record Official record
Conditions
Cardiovascular Diseases, Hyperlipidemias
Interventions
Lipid Challenge, Glucose Challenge, Mixed Meal Challenge
Dietary Supplement
Lead sponsor
Emory University
Other
Eligibility
18 Years to 50 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 30, 2023 · Synced Sep 12, 2026, 10:02 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Effect of Crestor on Lipoprotein Metabolism in Humans

NCT00214617
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Rosuvastatin at 5 mg/day and 40 mg/day
Drug
Lead sponsor
Foundation for Atlanta Veterans Education and Research, Inc.
Other
Eligibility
50 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 19, 2017 · Synced Sep 12, 2026, 10:02 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety, Pharmacokinetic Study of RVX000222 in Healthy Subjects and Subjects With Low HDL Cholesterol

NCT00768274
View directory record Official record
Conditions
Dyslipidemia, Atherosclerosis, Acute Coronary Syndrome, Cardiovascular Disease
Interventions
RVX000222, Placebo
Drug
Lead sponsor
Resverlogix Corp
Industry
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 3, 2022 · Synced Sep 12, 2026, 10:02 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Apolipoprotein CIII Reduction Via Colchicine

NCT02083510
View directory record Official record
Conditions
Hypertriglyceridemia, Gout, Pericarditis
Interventions
Colchicine
Drug
Lead sponsor
Scripps Translational Science Institute
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated May 29, 2014 · Synced Sep 12, 2026, 10:02 PM EDT
Completed Phase 2 Interventional Results available

A Study of Alirocumab in Participants With Autosomal Dominant Hypercholesterolemia (ADH) and Gain-of-Function Mutations (GOFm) of the Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Gene or Loss-of-Function Mutations (LOFm) of the Apolipoprotein (Apo) B Gene

NCT01604824
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Alirocumab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 16, 2020 · Synced Sep 12, 2026, 10:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Determine the Effects of Multiple Doses of Mipomersen (200 mg SC) on the Pharmacodynamics and Pharmacokinetics of Single-dose Warfarin

NCT01133366
View directory record Official record
Conditions
Healthy
Interventions
warfarin sodium, mipomersen sodium; warfarin sodium
Drug
Lead sponsor
Kastle Therapeutics, LLC
Industry
Eligibility
18 Years to 45 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 2, 2016 · Synced Sep 12, 2026, 10:02 PM EDT
Terminated Phase 3 Interventional Results available

Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients

NCT00667810
View directory record Official record
Conditions
Alzheimer Disease
Interventions
bapineuzumab, placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
50 Years to 89 Years
Enrollment
901 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
164
States / cities
Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 98 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2016 · Synced Sep 12, 2026, 10:02 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

GeneMatch: A Program of the Alzheimer's Prevention Registry to Match Individuals to Studies Based on Apolipoprotein E (APOE) Genotype

NCT02564692
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Not listed
Lead sponsor
Banner Health
Other
Eligibility
50 Years to 90 Years
Enrollment
500,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2030
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Sep 12, 2026, 10:02 PM EDT
Withdrawn Phase 2 Interventional

Clinical Trial of AGB101 for Mild Cognitive Impairment

NCT05986721
View directory record Official record
Conditions
Mild Cognitive Impairment, Prodromal Alzheimer's Disease
Interventions
AGB101, Placebo
Drug
Lead sponsor
AgeneBio
Industry
Eligibility
55 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 24, 2025 · Synced Sep 12, 2026, 10:02 PM EDT
Recruiting Not applicable Interventional

Impact of the Corrie Lipids Digital Health Program on Lipid Optimization

NCT07478887
View directory record Official record
Conditions
Cardiovascular Risk, LDL-C, Lipids, Digital Health, Implementation Science
Interventions
Corrie Lipids Digital Health Program
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Sep 12, 2026, 10:02 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Cannabis Effects on Brain Morphology in Aging

NCT01874886
View directory record Official record
Conditions
Study Focuses on Brain Morphology and Cognition in Older Subjects
Interventions
Not listed
Lead sponsor
University of California, Los Angeles
Other
Eligibility
60 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 2, 2020 · Synced Sep 12, 2026, 10:02 PM EDT
Completed Phase 3 Interventional Results available

Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease

NCT00428090
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Rosiglitazone
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years to 90 Years
Enrollment
862 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
41
States / cities
Phoenix, Arizona • Los Angeles, California • Newport Beach, California + 34 more
Source: ClinicalTrials.gov public record
Updated May 18, 2017 · Synced Sep 12, 2026, 10:02 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Evaluating Simvastatin's Potential Role in Therapy

NCT00486044
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Simvastatin, Placebo
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
35 Years to 69 Years
Enrollment
103 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 4, 2019 · Synced Sep 12, 2026, 10:02 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

ALA-enriched Nutrition for Prevention of Cognitive Decline in APOE4 Older Adults

NCT07392723
View directory record Official record
Conditions
Cognitive Dysfunction, Alzheimer Disease, Blood-Brain Barrier, Apolipoprotein E, Deficiency or Defect of, Brain Aging, Fatty Acids, Omega-3
Interventions
Alpha-Linolenic Acid (2.6 g/day), Placebo Control Group
Drug · Dietary Supplement
Lead sponsor
Michal Schnaider Beeri, Ph.D.
Other
Eligibility
60 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Sep 12, 2026, 10:02 PM EDT
Completed Phase 2 Interventional Results available

Combined Effects of Non-statin Treatments on Apolipoprotein A-I Up-Regulation (CENTAUR): A Feasibility Study

NCT00728910
View directory record Official record
Conditions
Dyslipidemia
Interventions
Atorvastatin, ABT335, ER Niacin
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 28, 2016 · Synced Sep 12, 2026, 10:02 PM EDT
Terminated Phase 3 Interventional Results available

Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients

NCT00676143
View directory record Official record
Conditions
Alzheimer Disease
Interventions
bapineuzumab, placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
50 Years to 88 Years
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
111
States / cities
Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2016 · Synced Sep 12, 2026, 10:02 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Oral Versus Patch Hormonal Contraceptive Effects on Metabolism, Clotting, Inflammatory Factors and Vascular Reactivity

NCT00439972
View directory record Official record
Conditions
Contraception
Interventions
Ortho-Cyclen (R), Ortho Evra (R), extended use of Ortho Evra (R)
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 13, 2011 · Synced Sep 12, 2026, 10:02 PM EDT
Completed Not applicable Interventional

Soybean Based Diets and CVD Risk Factors

NCT00175097
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Diet: soybeans and products made thereof, Diet: soybean flour and products made thereof, Diet: soybean milk, Diet: Animal protein based diet
Other
Lead sponsor
Tufts University
Other
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 1, 2014 · Synced Sep 12, 2026, 10:02 PM EDT